» Articles » PMID: 20723990

Conjunctival Melanoma: Outcomes Based on Tumor Origin in 382 Consecutive Cases

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 2010 Aug 21
PMID 20723990
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate prognostic factors based on origin of conjunctival melanoma.

Design: Interventional case series.

Participants: Three hundred eighty-two consecutive patients.

Methods: Retrospective chart review.

Main Outcome Measures: Melanoma-related metastasis and death.

Results: The melanoma arose from primary acquired melanosis (PAM; n = 284; 74%), from pre-existing nevus (n = 26; 7%), and de novo (n = 72; 19%). The mean tumor base was 11 mm for melanoma arising from PAM, 6 mm for melanoma arising from nevus, and 10 mm for those arising de novo. At 5 years (10 years), melanoma metastasis occurred in 19% (25%) in melanoma arising from PAM (P = 0.003), 10% (26%) in melanoma from nevus (P = 0.193), and 35% (49%) in those de novo. Factors predictive of metastasis by multivariable analysis included tumor origin de novo (P = 0.001), palpebral location (P<0.001), nodular tumor (P = 0.005), and orbital invasion (P = 0.022). At 5 years (10 years), melanoma-related death occurred in 5% (9%) in melanoma arising from PAM (P<0.001), 0% (9%) in melanoma arising from nevus (P<0.057), and 17% (35%) in those arising de novo. Factors predictive of death by multivariable analysis included tumor origin de novo (P<0.001), fornix location (P = 0.04), and nodular tumor (P = 0.001).

Conclusions: Melanoma arising de novo carries a higher risk of melanoma-related metastasis and death compared with those cases arising from PAM or nevus.

Citing Articles

Clinical efficacy and safety of proton radiotherapy for ocular conjunctival malignancies: a systematic review and meta-analysis.

Zheng T, Wang D, Miao Y, Dong M, Liu Q, Zhang Q Front Public Health. 2025; 13:1486988.

PMID: 40008149 PMC: 11850267. DOI: 10.3389/fpubh.2025.1486988.


Epigenetics of Conjunctival Melanoma: Current Knowledge and Future Directions.

Flick K, Demirci H, Demirci F Cancers (Basel). 2024; 16(21).

PMID: 39518125 PMC: 11544918. DOI: 10.3390/cancers16213687.


Conjunctival Melanoma: A Clinical Review and Update.

Butt K, Hussain R, Coupland S, Krishna Y Cancers (Basel). 2024; 16(18).

PMID: 39335093 PMC: 11429624. DOI: 10.3390/cancers16183121.


Conjunctival melanoma with pronounced central corneal invasion: One-year relapse free follow-up.

Englisch C, Berger T, Flockerzi F, Bofferding M, Seitz B Am J Ophthalmol Case Rep. 2024; 36:102162.

PMID: 39286547 PMC: 11403272. DOI: 10.1016/j.ajoc.2024.102162.


Adjuvant Brachytherapy with Ruthenium-106 to Reduce the Risk of Recurrence of Conjunctival Melanoma after Excision.

Grajewski L, Kneifel C, Wosle M, Ciernik I, Krause L Ocul Oncol Pathol. 2024; 10(3):162-167.

PMID: 39224526 PMC: 11368392. DOI: 10.1159/000539684.